Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer

Launched by LAHEY CLINIC · Mar 27, 2009

Keywords

ClinConnect Summary

This clinical trial is studying whether analyzing DNA and protein found in urine can help detect urothelial cancer, which affects the bladder and kidneys. The researchers want to see if this urine test can provide information about how the cancer might behave, including whether it could come back after treatment. The trial is currently looking for participants, including those who are about to have surgery for bladder cancer or who are in follow-up for recurrent disease. They also need a control group of people with no evidence of bladder cancer.

To be eligible for the trial, participants must be at least 18 years old and scheduled for certain procedures like nephroureterectomy or cystectomy. If you join the study, you'll provide urine samples, which will be tested to see if this non-invasive method can effectively identify urothelial cancer. This could potentially lead to better ways of monitoring and treating the disease. If you're interested and meet the criteria, consider discussing this opportunity with your healthcare provider.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients scheduled to have a nephroureterectomy, cystectomy, cytoscopy (newly diagnosed bladder cancer and those with recurrent disease in follow up)
• • Control Group: No known evidence of bladder cancer-one urine sample
• • \> than 18 years of age
• Exclusion Criteria:
• • \< than 18 years of age